GRP-02Delivery risk: AmberGate: pending
Turn research into products and adoption
A broad priority grouping A41, A42; its scores are its own, never an average of its members.
Provisional single-reviewer assessment; not an approved business case.
- Who and where
- Population not yet defined. Jurisdiction: not defined.
- Result so far
- Range if completed: 11.0–20.0 out of 30 (equal weights; not yet assessed: increment beyond baseline (Ad), expected incremental benefit (Bn), incremental affordability (Co))
- Funded now (baseline)
- Funded baseline not yet stated
- The change assessed (marginal)
- Marginal change not yet defined
- Domain home: Innovation
- In the national plan: Growth and prosperity list
What the evidence supports—and the next decision
Grant evaluation cannot establish the effect of a combined research, procurement and adoption package.
AI-assisted analytical follow-up · 8 October 2026. Proposed appraisal design; the attributed scores below are unchanged. No funding or delivery agreement is implied.
- Define the change
- Separate research grants, first-customer procurement and adoption support. Define eligible firms and what they already receive.
- Test whether it works
- Additional private research and commercial sales, then productivity and survival against comparison firms; distinguish displacement from new activity.
- Establish the cost
- Public grants and administration, procurement liabilities and private contributions. Do not add turnover, wages and productivity benefits if they describe the same gain.
- Protect against harm
- Use transparent selection, conflict controls and publication of failed projects as well as successes.
Read with the outcome evidence and sources in the full assessment. Monitoring proposals are not existing baseline measurements. A numerical benefit or cost score needs evidence for the defined increment, not just the scale of the problem.
Full assessment of Turn research into products and adoption: ten criteria, scenarios, delivery, costs and monitoring
The ten criteria (0–3)
Each criterion is scored 0 to 3 by the reviewer. “Not yet assessed” means unknown: it is never counted as zero.
Scale and severity (Sc)2 of 3 — Serious harm to a defined group or widespread moderate harm
Reviewer’s reason: Provisional problem-importance judgement from linked site pages; not the scale of achievable benefit.
Increment beyond baseline (Ad)Not yet assessed
Reviewer’s reason: Separate spinout terms, procurement trials, grants and firm adoption; define market failure, beneficiaries and comparator. A missing rating requires a defined marginal change.
Confidence in the proposed action (Ev)1 of 3 — Indirect, mixed, modelled or weak causal support
Reviewer’s reason: The artifact offers weak support for its spinout/procurement package. Smart Grants evaluation is relevant to a different instrument and cannot validate the whole bundle.
Expected incremental benefit (Bn)Not yet assessed
Reviewer’s reason: Unknown unless a reasonably defined target-population benefit can be judged; no bonus merely for spanning domains.
Residual harms (Hm)2 of 3 — Manageable harm with specified safeguards
Reviewer’s reason: Deadweight subsidies; concentrated gains; failed investments.
Incremental affordability (Co)Not yet assessed
Reviewer’s reason: Administration, grants, procurement risk and private match; estimate displacement and additional private investment.
Delivery capacity (Ca)2 of 3 — Stretched but plausibly obtainable
Reviewer’s reason: Separate spinout terms, procurement trials, grants and firm adoption; define market failure, beneficiaries and comparator.
Distribution (Fa)1 of 3 — Material disadvantage to vulnerable groups
Reviewer’s reason: Provisional distribution judgement for the stated target; verify who pays, who gains and excluded groups.
Meaningful first outcome (Ti)1 of 3 — More than three but less than ten years
Reviewer’s reason: First meaningful outcome, not announcement: Additional adoption, productivity and commercial outcomes versus comparable firms.
Readiness (Rd)2 of 3 — Named commissioning/allocation/coordination step
Reviewer’s reason: Business/research departments, UKRI and public buyers; Split and appraise alternatives
Four weightings
Normalised as 10 × weighted sum ÷ sum of weights, on a 0–30 scale. Where a criterion is not yet assessed, the range is the lowest and highest result if it were later scored 0 or 3 — not a score, a confidence interval or a rank.
- Equal weights: Range if completed: 11.0–20.0 out of 30. Not yet assessed: increment beyond baseline (Ad), expected incremental benefit (Bn), incremental affordability (Co). Funding gate: not passed.
- Evidence doubled: Range if completed: 10.9–19.1 out of 30. Not yet assessed: increment beyond baseline (Ad), expected incremental benefit (Bn), incremental affordability (Co). Funding gate: not passed.
- Scale doubled: Range if completed: 11.8–20.0 out of 30. Not yet assessed: increment beyond baseline (Ad), expected incremental benefit (Bn), incremental affordability (Co). Funding gate: not passed.
- Cost ignored (the funding gate still applies): Range if completed: 12.2–18.9 out of 30. Not yet assessed: increment beyond baseline (Ad), expected incremental benefit (Bn), incremental affordability (Co). Funding gate: not passed.
Funding gate: Not passed — the cost is not yet assessed or no allocation is committed for this scope. Ignoring cost in a weighting never removes the gate.
Delivery risk and gate
Delivery risk shown: AmberReview’s claim: Amber. Best the recorded evidence allows: Amber.
Review’s reason: Administration, grants, procurement risk and private match; estimate displacement and additional private investment.
Why it is not Green yet
- Scope (population, place and increment) not verified against the delivery baseline.
- No verified owner with the powers in place.
- Delivery capacity not verified.
- Lifetime incremental costs not complete.
- No credible funding (a committed allocation for the scope).
- Safeguards not specified.
- Monitoring lacks a metric, a data source or a baseline.
Green needs verified scope, a verified owner with the powers, verified capacity, complete lifetime costs with credible funding, specified safeguards and monitoring with a metric, source and baseline. Amber means appraisal gaps remain; Red means a material delivery obstacle. Red does not mean unimportant.
Gate: Pending — appraisal incomplete (review label: “Pending: incomplete appraisal”).
Why: Scores incomplete; Funding gate not passed (cost unknown or no credible funding).
The gate is separate from national list membership: being listed does not make an option eligible, and an eligible option need not be listed.
Cost and funding
Lifetime costing: Not established. Review: “Full incremental costing not established in reviewed material”.
Still to cost: Administration, grants, procurement risk and private match; estimate displacement and additional private investment.
Funding status: not established in review.
Owner, powers and capacity
Proposed owner: Business/research departments, UKRI and public buyers (proposed, unverified).
Powers: needs a decision or allocation. Capacity: unverified.
Powers and capacity read from the review’s Rd and Ca anchors; no proposed owner has agreed to act (the review: “Proposed owners have not agreed to act”).
- England:
- not assessed
- Scotland:
- not assessed
- Wales:
- not assessed
- Northern Ireland:
- not assessed
Not defined in the review.
Dependencies, safeguards and risks
Depends on: None recorded.
Safeguards
None specified yet.
Risks and residual harms: Deadweight subsidies; concentrated gains; failed investments.
Monitoring and measured results
Metric: Additional adoption, productivity and commercial outcomes versus comparable firms.
Data source: Not yet named. Baseline: Not yet established.
Measures already on the domain page
- Active university spin-outs: latest 1,695 (September 2025); baseline not published (United Kingdom).
- Equity finance raised by smaller businesses: latest £12.3bn (2025); baseline not published (United Kingdom).
A page measure is not necessarily the review’s metric; linking the two is an editorial decision still to be made.
Evidence for the outcome
Outcome: Additional adoption, productivity and commercial outcomes versus comparable firms.
The artifact offers weak support for its spinout/procurement package. Smart Grants evaluation is relevant to a different instrument and cannot validate the whole bundle.
Sources: ukri.org (not yet in the source register)
SWOT points it addresses
- The first national spin-out register records 2,307 university spin-outs, 1,695 of them active. (Innovation)
- Standard deal terms and proof-of-concept money for spin-outs, plus public bodies acting as tested first customers, could move more research into use. (Innovation)
- Spending and spin-out counts do not show economic or social returns: the flagship technology-adoption scheme found no statistically significant productivity effect, and the spin-out review offers recommendations rather than measured outcomes. (Innovation)
- Finance gaps at the scale-up stage, weak demand and pilots without buyers can stop promising research reaching use. (Innovation)
Review record
Assessment status: Provisional single-reviewer assessment; not an approved business case.
Reviewer: Original assessment author (name not supplied). Reviewed: 6 October 2026.
Scored in the working review of 6 October 2026 on the shared ten-criterion scale (one reviewer); not independently calibrated.
First 90 days (review): Produce a signed scope and current-delivery baseline; Separate spinout terms, procurement trials, grants and firm adoption; define market failure, beneficiaries and comparator. Obtain incremental costs and an accountable decision before expansion.
Decision route: Split and appraise alternatives
An editorial screening framework by one reviewer, not a formal appraisal or business case. Proposed owners have not agreed to act.